Home › Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia clinical trials recruiting in the U.S.
120 studies for Chronic Lymphocytic Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
- Boston, MA31 studies
- Columbus, OH28 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA20 studies
- Rochester, MN19 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI15 studies
- Cincinnati, OH14 studies
- Chicago, IL14 studies
- Nashville, TN13 studies
- Jacksonville, FL11 studies
- Philadelphia, PA11 studies
- Atlanta, GA11 studies
- Dallas, TX10 studies
- Portland, OR10 studies
- Salt Lake City, UT10 studies
- Kansas City, MO10 studies
- San Diego, CA10 studies
- Pittsburgh, PA10 studies
- Denver, CO9 studies
- Charlotte, NC9 studies
- Miami, FL9 studies
- St. Louis, MO8 studies
- Los Angeles, CA8 studies
- Des Moines, IA8 studies
- Omaha, NE8 studies
- Winston-Salem, NC8 studies
- Queens, NY8 studies
- Tampa, FL8 studies
- Minneapolis, MN8 studies
- Cleveland, OH8 studies
- Clifton, NJ7 studies
- Aurora, CO7 studies
- Mountain View, CA7 studies
- Cedar Rapids, IA7 studies
- Fort Wayne, IN7 studies
- Detroit, MI7 studies
By state
- Alabama7 studies
- Arizona15 studies
- Arkansas4 studies
- California33 studies
- Colorado17 studies
- Connecticut4 studies
- Delaware4 studies
- District of Columbia4 studies
- Florida34 studies
- Georgia16 studies
- Idaho4 studies
- Illinois17 studies
- Indiana12 studies
- Iowa10 studies
- Kansas6 studies
- Kentucky7 studies
- Louisiana6 studies
- Maine6 studies
- Maryland23 studies
- Massachusetts33 studies
- Michigan12 studies
- Minnesota29 studies
- Mississippi5 studies
- Missouri13 studies
- Montana7 studies
- Nebraska8 studies
- Nevada6 studies
- New Hampshire3 studies
- New Jersey13 studies
- New Mexico3 studies
- New York26 studies
- North Carolina34 studies
- Ohio43 studies
- Oklahoma4 studies
- Oregon16 studies
- Pennsylvania22 studies
- Rhode Island6 studies
- South Carolina5 studies
- South Dakota3 studies
- Tennessee17 studies
- Texas38 studies
- Utah10 studies
- Virginia12 studies
- Washington26 studies
- Wisconsin19 studies
Recently updated studies
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Oct 2, 2026 · NCT05724121Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RecruitingPhase 1
Up to age 75 · All sexes · Updated Oct 2, 2026 · NCT01853631Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Oct 2, 2026 · NCT07321652Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06863402Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07582432Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT03516617A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06943872Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
RecruitingPhase 2
Ages 75 and older · All sexes · Updated Sep 28, 2026 · NCT07685717A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06846671A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Sep 28, 2026 · NCT00923507Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 24, 2026 · NCT03986034A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06136559Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06784167Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT01087333A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.